Exelixis Inc. (EXEL)
NASDAQ: EXEL
· Real-Time Price · USD
39.01
-0.14 (-0.36%)
At close: Sep 15, 2025, 3:59 PM
39.13
0.31%
After-hours: Sep 15, 2025, 06:36 PM EDT
-0.36% (1D)
| Bid | 37.88 |
| Market Cap | 10.5B |
| Revenue (ttm) | 2.23B |
| Net Income (ttm) | 602.3M |
| EPS (ttm) | 2.08 |
| PE Ratio (ttm) | 18.75 |
| Forward PE | 14.01 |
| Analyst | Buy |
| Ask | 39.5 |
| Volume | 1,986,025 |
| Avg. Volume (20D) | 3,283,022 |
| Open | 39.12 |
| Previous Close | 39.15 |
| Day's Range | 38.40 - 39.17 |
| 52-Week Range | 25.17 - 49.62 |
| Beta | 0.32 |
About EXEL
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol EXEL
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for EXEL stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Exelixis Inc. is scheduled to release its earnings on
Oct 28, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
-16.78%
Exelixis shares are trading lower after the compan...
Unlock content with
Pro Subscription
1 month ago
-2.65%
Exelixis shares are trading lower after the company reported worse-than-expected Q2 revenue results.
3 weeks ago · seekingalpha.com
Exelixis: RCC Stronghold, NET Launch, And A CRC Readout That MattersCABOMETYX remains the leading TKI in renal cell carcinoma, driving strong revenue growth and expanding into new indications like neuroendocrine tumors. Exelixis's pipeline, led by zanzalintinib, shows...